Cholangiocarcinoma (CCA) is a heterogeneous and devastating type of cancer that develops from biliary cells in the biliary tract. Among the different subtypes of CCA, intrahepatic CCA (iCCA) accounts for 15% of primary liver tumors and has become a growing health problem over the past decades.1,2 Large-scale genomic studies have enabled the identification of the most frequent oncogenic mutational events found in human tumors, which include alterations in TP53 (20%), CDKN2A (15%), RAS (15%), BAP1 (15%), IDH1/2 (15%), and FGFR2 fusions (10%).